| Literature DB >> 34499029 |
Luca Tirinato1,2, Maria Grazia Marafioti1,2, Francesca Pagliari1, Jeannette Jansen1,3, Ilenia Aversa1,2, Rachel Hanley1, Clelia Nisticò1,2, Daniel Garcia-Calderón1,3, Geraldine Genard1, Joana Filipa Guerreiro4, Francesco Saverio Costanzo2, Joao Seco1,3.
Abstract
Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma, and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of lipid droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect that might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.Entities:
Keywords: cancer; cancer biology; ferritin heavy chain; human; iron metabolism; lipid droplets; radioresistance
Mesh:
Substances:
Year: 2021 PMID: 34499029 PMCID: PMC8497056 DOI: 10.7554/eLife.72943
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140
Figure 1.Lipid droplet detection in neuroglioma (H4), lung (H460), breast (MCF7), prostate (PC3), and bladder (T24) 6 Gy X-ray-resistant cancer cells.
Cancer cells have been irradiated with 6 Gy X-ray and left in culture for 72 hrs. Afterwards, surviving and untreated cells have been stained with LD540 and imaged at the fluorescence confocal microscope. Z-projection of the z-stack acquisitions for untreated and 6 Gy treated cells are reported in column (A) (Scale bar, 20 μM). (B) For each cell line, 50 cells have been randomly imaged, and their LD number counted by using FiJi software. (C) qPCR analysis of the PLIN genes in the indicated cell lines. PLIN5 in the H4 6 Gy treated cells is not reported in the graph because it was not expressed. Error bars represent the means ± SD from three independent experiments. *≤0.05; **≤0.01; ***≤0.001, and ****≤0.0001.
Figure 1—figure supplement 1.ROS evaluation in 6 Gy radioresistant cancer cells.
Figure 1—figure supplement 2.ROS and Lipid Droplet Double Staining in Different Cancer Cell Lines.
Figure 1—figure supplement 3.CSC Marker Evaluation in 6 Gy Radioresistant Cells.
Figure 2.Cell survival curves for H4, H460, MCF7, PC3, and T24 cancer cell lines.
All cancer cell lines were stained with LD540 and then sorted in the 10% highest and lowest LD-containing cells (box up-left). For each cell line, the two LD sub-populations were irradiated at 2, 4, and 6 Gy X-ray and their survival fraction calculated. Survival fractions are reported in log-linear scale. Error bar represents the means ± SD from three independent experiments. *≤0.05; **≤0.01; ***≤0.001, and ****≤0.0001.
Figure 3.FTH1 silencing downregulates lipid droplets affecting cancer radioresistance.
(A, B) Wester blotting analysis and quantification of FTH1 expression in MCF7−, H460−, H4−, PC3−, T24- 0 Gy vs 6 Gy X-ray-treated cells. HSC70 was used as a loading control. (C) H460 and MCF7 were sorted in the 10% Highest (H460 LDHigh and MCF7 LDHigh) and Lowest (H460 LDLow and MCF7 LDLow) LD-containing cells and then FTH1 mRNA expression measured by qRT-PCR in all four sub-populations. Primer sequences are listed in Key resource table. (D) H460 and MCF7 were silenced for FTH1 by lentiviral-driven shRNA strategy. PCR results showed that in H460 shFTH1 and MCF shFTH1 there was a clear FTH1 mRNA reduction compared with their relative controls. (E, F) LD content was measured and quantified in H460 shFTH1 and MCF7 shFTH1 by confocal microscopy. LD540 staining revealed that the FTH1 gene silencing caused a LD decrease in both cell systems. (Scale bars 20 μM). (G) Cellular irradiation response in H460 and MCF7 silenced for FTH1 was investigated by radiobiological clonogenic assay and compared with H460 shRNA and MCF7 shRNA, respectively. Survival fraction (in log-linear scale) is reported in (G). Error bar represents the means ± SD from three independent experiments. *≤0.05; **≤0.01; ***≤0.001, and ****≤0.0001.
Figure 3—figure supplement 1.TfR1 downregulation and FPN upregulation in FTH1-silenced H460 and MCF7 cells.
Figure 4.FTH1 reconstitution as well as DFO treatment restore the LD content re-establishing cancer radioresistance.
(A-B) Western Blotting analysis and quantification of FTH1 expression in MCF7 shFTH1/pcDNA3FTH1 and H460 shFTH1/pcDNA3FTH1. HSC70 was used as loading control. (C) Z-stack representative confocal fluorescence images of LD detection and quantification (D) in MCF7 shFTH1/pcDNA3FTH1 and H460 shFTH1/pcDNA3FTH1 cells and their H460 shFTH1/pcDNA3 and MCF7 shFTH1/pcDNA3 controls. (Scale bars 20 mM). (E) Survival fractions (in log-linear scale) after FTH1 reconstitution in MCF7- and H460- shFTH1 cells. (F) Z-stack representative confocal fluorescence images of LD detection and quantification (G) in MCF7 shFTH1 and H460 shFTH1 treated with DFO (Scale bar 20 mM). (H) Survival curves (in log-linear scale) of FTH1-silenced MCF7 and H460 cells after DFO treatment. F. Error bar represents the means ± SD from three independent experiments. *£ 0.05; **£ 0.01; ***£ 0.001 and ****£ 0.0001.
Figure 5.Schematic representation of a putative model at the basis of the cancer radioresistance (Created withBioRender.com).
Figure 5—figure supplement 1Keplan-Meier curves showing the Survival Probability related to the PLIN1-5, FTH1, TFR1 and FPN gene expression.
| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|---|---|---|---|---|
| Cell line ( | MCF-7 | ATCC | Cat# HTB-22 RRID: | |
| Cell line ( | H4 | ATCC | Cat# HTB-148 RRID: | |
| Cell line ( | H460 | ATCC | Cat# HTB-177 RRID: | |
| Cell line ( | T24 | ATCC | Cat# HTB-4 RRID: | |
| Cell line ( | PC3 | ATCC | Cat# CRL-1435 RRID: | |
| Antibody | (Goat polyclonal) anti-human FTH1 | Santa Cruz Biotechnology | Cat# sc-14416 RRID: | WB(1:200) |
| Antibody | (Goat polyclonal) anti-human HSC70 | Santa Cruz Biotechnology | Cat# sc-1059 RRID: | WB (1:2000) |
| Antibody | (Goat polyclonal) anti-mouse IgG-HRP | Santa Cruz Biotechnology | Cat# sc-20550 RRID: | WB (1:2000) |
| Recombinant DNA reagent | pLKO.1 | Addgene (gift from F.S. Costanzo) | ||
| Recombinant DNA reagent | pcDNA3 | Addgene (gift from F.S. Costanzo) | ||
| Chemical compound, drug | CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 | |
| Chemical compound, drug | Nile Red | Thermo Fisher Scientific | Cat# N1142 | |
| Chemical compound, drug | Deferoxaminemesylate | Sigma-Aldrich | Cat# D9533 | |
| Chemical compound, drug | Puromycin dihydrochloride | Acros organics | Cat# BP2965 | |
| Chemical compound, drug | Power SYBR Green PCR Master mix | Thermo Fisher Scientific | Cat# 4367659 | |
| Chemical compound, drug | LD540 | Synthetised by Enamine | ||
| Commercial assay or kit | Pierce BCA Protein Assay Kit | Thermo Fisher Scientific | Cat# 23,225 | |
| Commercial assay or kit | High Pure isolation RNA kit | Roche | Cat# 11828665001 | |
| Commercial assay or kit | RT2 First strand Kit (50) | Qiagen | Cat# 330,404 | |
| Commercial assay or kit | Lipofectamine 3000 Transfection Reagent | Thermo Fisher Scientific | Cat# L3000075 | |
| Sequence-based reagent | Custom-made qPCR primers – GAPDH | Sigma-Aldrich | Forward – 5'-GCATCCTGGGCTACACTGAG-3' Reverse – 5'-AAAGTGGTCGTTGAGGGCA-3' | |
| Sequence-based reagent | Custom-made qPCR primers – FTH1 | Sigma-Aldrich | Forward – 5′-CATCAACCGCCAGATCAAC-3 Reverse –5′-GATGGCTTTCACCTGCTCAT-3′ | |
| Sequence-based reagent | Custom-made qPCR primers – TfR1 | Sigma-Aldrich | Forward – 5'-CTGGTAAACTGGTCCATGCT-3' Reverse – 5'-GTGATTTTCCCTGCTCTGAC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – FPN | Sigma-Aldrich | Forward – 5'-GGTGTCTGTGTTTCTGGT-3' Reverse – 5'-GTCTAGCATTCTTGTCCAC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – CD24 | Sigma-Aldrich | Forward – 5’-CCTGTCAGAGCTGTGTGGAC-3’ Reverse – 5’-GCTGGGTAGAGTGGTGTGT-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – CD44 | Sigma-Aldrich | Forward – 5’-GGGTTCATAGAAGGGCACGT-3’ Reverse – 5’-GGGAGGTGTTGGATGTGAGG-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – CD133 | Sigma-Aldrich | Forward – 5’-AAGCATTGGCATCTTCTATGG-3’ Reverse – 5‘-AGAGAGTTCGCAAGTCCTTG-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – CD166 | Sigma-Aldrich | Forward – 5‘-CGATGAGGCAGACGAGATAAG-3’ Reverse – 5‘-TAGACGACACCAGCAACAAG-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – ALDH1 | Sigma-Aldrich | Forward – 5’-AACTGGAATGTGGAGGAGGC-3’ Reverse – 5’-ATGATTTGCTGCACTGGTCC-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – PLIN1 | Sigma-Aldrich | Forward – 5'-GACAAGGAAGAGTCAGCCCC-3' Reverse – 5'-GAGAGGGTGTTGGTCAGAGC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – PLIN2 | Sigma-Aldrich | Forward – 5'-ACAGGGGTGATGGACAAGAC-3' Reverse – 5'-ATCATCCGACTCCCCAAGAC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – PLIN3 | Sigma-Aldrich | Forward – 5'-CACCATGTTCCGGGACATTG-3' Reverse – 5'-GCACCTGGTCCTTCACATTG-3' | |
| Sequence-based reagent | Custom-made qPCR primers – PLIN4 | Sigma-Aldrich | Forward – 5’- GTTCCAGGACCACAGACA-3’ Reverse – 5’CCTACACTGAGCACATCC-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – PLIN5 | Sigma-Aldrich | Forward – 5'-GATCACTTCCTGCCCATGAC-3' Reverse – 5'-GCTGTCTCCTCTGATCCTCC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – SOD1 | Sigma-Aldrich | Forward – 5'-GCAGATGACTTGGGCAAAGG-3' Reverse – 5'-TGGGCGATCCCAATTACACC-3' | |
| Sequence-based reagent | Custom-made qPCR primers – SOD2 | Sigma-Aldrich | Forward – 5'-CTGGAACCTCACATCAACGC-3' Reverse – 5'-CCTGGTACTTCTCCTCGGTG-3' | |
| Sequence-based reagent | Custom-made qPCR primers – GPX1 | Sigma-Aldrich | Forward – 5’-CCCAAGCTCATCACCTGGTC-3’ Reverse – 5’-TGTCAATGGTCTGGAAGCGG-3’ | |
| Sequence-based reagent | Custom-made qPCR primers – Catalase | Sigma-Aldrich | Forward – 5'-CGTGCTGAATGAGGAACAG-3' Reverse – 5'-GACCGCTTTCTTCTGGATG-3' |